MENU
+Compare
IPHA
Stock ticker: NASDAQ
AS OF
Mar 11, 04:56 PM (EDT)
Price
$2.09
Change
+$0.03 (+1.46%)
Capitalization
183.52M

IPHA Innate Pharma SA Forecast, Technical & Fundamental Analysis

Innate Pharma SA is a clinical-stage biotechnology company... Show more

IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for IPHA with price predictions
Mar 10, 2025

IPHA in upward trend: price rose above 50-day moving average on February 04, 2025

IPHA moved above its 50-day moving average on February 04, 2025 date and that indicates a change from a downward trend to an upward trend. In of 75 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for IPHA crossed bullishly above the 50-day moving average on February 06, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 121 cases where IPHA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for IPHA moved out of overbought territory on February 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on March 04, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IPHA as a result. In of 120 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for IPHA turned negative on March 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IPHA broke above its upper Bollinger Band on February 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.724) is normal, around the industry mean (11.729). P/E Ratio (0.000) is within average values for comparable stocks, (64.632). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (6.390) is also within normal values, averaging (235.265).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IPHA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

IPHA is expected to report earnings to fall 500.00% to -7 cents per share on September 15

Innate Pharma SA IPHA Stock Earnings Reports
Q2'22
Est.
$-0.08
Q2'23
Beat
by $0.16
The last earnings report on September 14 showed earnings per share of 1 cents, beating the estimate of -14 cents. With 5.56K shares outstanding, the current market capitalization sits at 183.52M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
117, Avenue de Luminy
Phone
+33 430303030
Employees
211
Web
https://www.innate-pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGRWX27.93N/A
N/A
Barrett Growth Retail
FCCGX22.74N/A
N/A
Fidelity Advisor Small Cap Growth C
BUFTX22.58N/A
N/A
Buffalo Mid Cap Discovery
BDFUX31.92N/A
N/A
Baron Discovery R6
RWINX13.92-0.21
-1.49%
Redwood AlphaFactor Tactical Intl N

IPHA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IPHA has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IPHA jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHA
1D Price
Change %
IPHA100%
N/A
MDGL - IPHA
43%
Loosely correlated
-0.68%
SLNO - IPHA
34%
Loosely correlated
-2.46%
VALN - IPHA
30%
Poorly correlated
-2.40%
QSI - IPHA
28%
Poorly correlated
-8.91%
VKTX - IPHA
27%
Poorly correlated
-3.92%
More